Ze-Hou Wang, Zong-Jin Zhang, Yue-Fen Wang, Jin Xie, Yi-Min Li, Cun Shen, Yuan Meng, Wen-Jing Zhao, Lu-Ying Sun, Wei Jing Liu
{"title":"Serum advanced glycation end products as a putative biomarker in Type2 DKD patients' prognosis.","authors":"Ze-Hou Wang, Zong-Jin Zhang, Yue-Fen Wang, Jin Xie, Yi-Min Li, Cun Shen, Yuan Meng, Wen-Jing Zhao, Lu-Ying Sun, Wei Jing Liu","doi":"10.3389/fphys.2025.1541198","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>Advanced glycation end products (AGEs) are pivotal mediators in diabetic kidney disease (DKD). However, their prognostic utility remains underexplored. This study introduced corrected lgAGEs [novel biomarker derived by adjusting logarithmically transformed AGEs (lgAGEs) levels based on serum albumin (ALB) levels] to enhance the prediction of adverse renal outcomes in patients with type 2 DKD (T2DKD).</p><p><strong>Methods: </strong>In this prospective cohort study, 196 T2DKD patients were followed up longitudinally. Serum AGEs levels were log-transformed and adjusted for ALB to calculate corrected lgAGEs. Participants were stratified into the high- and low-level groups based on the median corrected lgAGEs. The association between corrected lgAGEs and renal outcomes was assessed using Cox proportional hazards models. Receiver operating characteristic (ROC) curve was utilized to evaluate the predictive performance of corrected lgAGEs alone and in combination with the urinary albumin-to-creatinine ratio (UACR).</p><p><strong>Results: </strong>High level of corrected lgAGEs was independently associated with adverse renal outcomes [hazard ratio (HR), 3.252; 95% confidence interval (CI), 1.461-7.243; <i>p</i> = 0.003]. Kaplan-Meier analysis demonstrated that patients in the high-level group (12 months) exhibited significantly shorter median survival times compared with those in the low-level group (50 months). ROC analysis showed that UACR alone had an area under the curve (AUC) of 0.782 (95% CI, 0.705-0.858), with 82.8% sensitivity and 61.5% specificity. Corrected lgAGEs achieved an AUC of 0.725 (95% CI, 0.637-0.814), with 69.0% sensitivity and 76.9% specificity. Combining UACR and corrected lgAGEs improved the specificity to 75.6%, with an AUC of 0.764 (95% CI, 0.682-0.847), while maintaining a sensitivity of 70.7%.</p><p><strong>Conclusion: </strong>Corrected lgAGEs are novel and independent biomarkers for predicting adverse renal outcomes in T2DKD. Combining UACR with corrected lgAGEs could enhance risk stratification by improving the specificity, highlighting its potential application in early identification of high-risk patients. These findings should be validated in broader populations in future research.</p>","PeriodicalId":12477,"journal":{"name":"Frontiers in Physiology","volume":"16 ","pages":"1541198"},"PeriodicalIF":3.2000,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11825471/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Physiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fphys.2025.1541198","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"PHYSIOLOGY","Score":null,"Total":0}
Serum advanced glycation end products as a putative biomarker in Type2 DKD patients' prognosis.
Aim: Advanced glycation end products (AGEs) are pivotal mediators in diabetic kidney disease (DKD). However, their prognostic utility remains underexplored. This study introduced corrected lgAGEs [novel biomarker derived by adjusting logarithmically transformed AGEs (lgAGEs) levels based on serum albumin (ALB) levels] to enhance the prediction of adverse renal outcomes in patients with type 2 DKD (T2DKD).
Methods: In this prospective cohort study, 196 T2DKD patients were followed up longitudinally. Serum AGEs levels were log-transformed and adjusted for ALB to calculate corrected lgAGEs. Participants were stratified into the high- and low-level groups based on the median corrected lgAGEs. The association between corrected lgAGEs and renal outcomes was assessed using Cox proportional hazards models. Receiver operating characteristic (ROC) curve was utilized to evaluate the predictive performance of corrected lgAGEs alone and in combination with the urinary albumin-to-creatinine ratio (UACR).
Results: High level of corrected lgAGEs was independently associated with adverse renal outcomes [hazard ratio (HR), 3.252; 95% confidence interval (CI), 1.461-7.243; p = 0.003]. Kaplan-Meier analysis demonstrated that patients in the high-level group (12 months) exhibited significantly shorter median survival times compared with those in the low-level group (50 months). ROC analysis showed that UACR alone had an area under the curve (AUC) of 0.782 (95% CI, 0.705-0.858), with 82.8% sensitivity and 61.5% specificity. Corrected lgAGEs achieved an AUC of 0.725 (95% CI, 0.637-0.814), with 69.0% sensitivity and 76.9% specificity. Combining UACR and corrected lgAGEs improved the specificity to 75.6%, with an AUC of 0.764 (95% CI, 0.682-0.847), while maintaining a sensitivity of 70.7%.
Conclusion: Corrected lgAGEs are novel and independent biomarkers for predicting adverse renal outcomes in T2DKD. Combining UACR with corrected lgAGEs could enhance risk stratification by improving the specificity, highlighting its potential application in early identification of high-risk patients. These findings should be validated in broader populations in future research.
期刊介绍:
Frontiers in Physiology is a leading journal in its field, publishing rigorously peer-reviewed research on the physiology of living systems, from the subcellular and molecular domains to the intact organism, and its interaction with the environment. Field Chief Editor George E. Billman at the Ohio State University Columbus is supported by an outstanding Editorial Board of international researchers. This multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide.